Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Milana 2022 | Pharma | 56.4% | 99th pct | 110 |
| H Bi-Georgia | Pharma | 39.9% | 91st pct | 110 |
| Alpaparm | Pharma | 34.4% | 84th pct | 110 |
| Mediniusi | Pharma | 10.9% | 41st pct | 110 |
| Ermed Georgia | Pharma | — | no FY data | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
| Line item | Mediniusi | Alpaparm | Milana 2022 | H Bi-Georgia | Ermed Georgia |
|---|---|---|---|---|---|
| Total Current Assets | 3,114 | 0 | 2,686 | 2,844 | — |
| Total Non-Current Assets | 432 | 2,342 | 0 | 19 | — |
| TOTAL ASSETS | 3,547 | 2,342 | 2,686 | 2,863 | — |
| Total Current Liabilities | 95 | 392 | 400 | 837 | — |
| Total Non-Current Liabilities | 172 | 0 | 0 | 0 | — |
| TOTAL LIABILITIES | 268 | 392 | 400 | 837 | — |
| Total Equity | 3,279 | 1,950 | 2,286 | 2,026 | — |
| Balance Check (Assets - L&E) | 0 | 0 | 0 | 0 | — |
| Total Debt | 172 | 0 | 0 | 0 | — |
| Cash & Equivalents | 92 | 246 | 134 | 46 | — |
| Net Debt | 80 | -246 | -134 | -46 | — |
Not every picked company reports every selected year — FY2024: no filing for Ermed Georgia. Those cells are left blank (no filing), not zero.